Previous 10 | Next 10 |
Assertio Therapeutics, Inc. (ASRT) Q1 2020 Earnings Conference Call May 11, 2020 8:30 AM ET Company Participants Max Nemmers - Director, Human Resources Arthur Higgins - President & Chief Executive Officer Dan Peisert - Senior Vice President & Chief Financial Officer C...
Assertio Therapeutics ( ASRT ) Q1 results : More news on: Assertio Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Assertio Therapeutics (NASDAQ: ASRT ): Q1 Non-GAAP EPS of $0.10 beats by $0.18 ; GAAP EPS of $0.58 beats by $0.78 . More news on: Assertio Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
-- Completed Strategic Asset Sales of NUCYNTA ® Franchise and Gralise ® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger with Zyla Life Sciences On Track and Expected to Close Shortly After the...
NEW YORK, NY / ACCESSWIRE / May 8, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger between Assertio Therapeutics, Inc. (NASDAQ:ASRT) and Zyla Life Sciences is fair to Assertio shareholders. If you are an Assertio shareholder and would like to ...
Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting Assertio Reaffirms its Ability to Achieve Upwards of $40 Million in Synergies Will Report First Quarter 2020 Financial Results on Monday, May 11, 2020 Prior to the Open of Markets LAKE ...
LAKE FOREST, Ill., April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash tender offers (the “Offers”) to purchase any and all of the...
NEW YORK, March 17, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, investigates whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed t...
Assertio Therapeutics (NASDAQ: ASRT ) and Zyla Life Sciences ( OTCQX:ZCOR ) have agreed to merge in an all-stock transaction. Under the terms of the deal, Zyla stockholders will receive 2.5 shares in the combined company for each Zyla share owned. More news on: Assertio Therapeutics, Inc...
Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million 1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue Growth and Creating Shareholder Value Arthur Higgins to Become the Non-Executive...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...